Top Therapeutics Companies in Europe

Tuesday, October 20, 2026

Delayed return to eating after major surgery can turn a planned recovery window into extended hospitalisation. Gastrointestinal dysfunction adds discomfort, delays bowel function, increases readmission risk and keeps scarce beds occupied. Failure to restart oral intake can also complicate discharge planning and prompt avoidable nutrition support. Clinical-stage therapies aimed at nutritional recovery must therefore do more than stimulate appetite in theory. They need a defined biological target and trial endpoints that reflect what matters after surgery, including food intake and the return of gastrointestinal function. Asset selection becomes difficult when one mechanism appear

Thursday, October 08, 2026

A drug candidate can look promising when it enters clinical development and still leave its developer facing some difficult decisions. Once human studies begin, the consequences of those decisions become more immediate. For companies working with clinical-stage pharmaceutical and therapeutic development solutions in Europe, attention is turning toward how development programs are planned as new evidence starts to come in. The move into clinical work changes the questions a development team has to answer. Earlier research may focus largely on whether a candidate has enough potential to justify further study. Once clinical

Thursday, October 08, 2026

Choosing an external development service can seem fairly simple until a pharmaceutical team starts going through the details. A provider may offer support for clinical-stage work, but the buyer still has to work out exactly what that means for the program. For European pharmaceutical and therapeutic developers, the line between external support and internal responsibility can affect how smoothly the arrangement works. The question often comes up during procurement. A company may know it needs additional help without having decided which parts of the development work should remain with its own team. That can depend on the

Thursday, October 08, 2026

Clinical development work often moves between a pharmaceutical company’s own team and outside specialists. Every time that work changes hands, there is a chance that information becomes unclear or that someone assumes another team is responsible. For companies using clinical-stage development solutions in Europe, this can become a practical issue when several groups are working on the same program. The difficulty may not be obvious when the relationship begins. At that point, the scope is still fresh, and people generally know what they are expected to do. The situation can change later. Staff responsibilities may s

Wednesday, July 10, 2024

Tune Therapeutics adds Chief Scientific Officer Derek Jantz, Ph.D., and General Counsel, Zachary Hale, J.D., to enhance precision genetic-tuning treatments. FREMONT, CA: "Dr. Jantz's experience in taking novel modalities from inception to preclinical and clinical-stage therapies makes him an ideal addition to our team. His knowledge in this area is unsurpassed, and we're eager to incorporate his scientific expertise as we advance our TEMPO genetic tuning platform," said Matt Kane, CEO of

Friday, June 07, 2024

European researchers are revolutionising longevity therapeutics by focusing on cellular senescence, telomere maintenance, sirtuins, gut microbiome manipulation, and mTOR signalling pathways. This work requires collaboration, open dialogues, and citizen engagement. FREMONT, CA: The quest for extended lifespans has fascinated humanity for millennia. This ancient aspiration is merging with science in Europe, driving a revolution in longevity therapeutics. European researchers are leading breakthroughs in understanding the ageing process. One primary focus is cellular senescence, where cells stop dividing and contribute to tissue dysf